Government Funded Until November 21; Action Needed to Finalize NIH Increase

Before departing for a two-week recess in late September, Congress passed a short-term continuing resolution (CR), H.R. 4378, to keep the government open through November 21, 2019.

The CR was needed because the House of Representatives and Senate had not finalized a Fiscal Year 2020 appropriations bill before October 1, the start of the fiscal year.

We have testified before Congress, visited key leaders, and conducted Hill Days, but we need to keep the pressure on.

While there were several differences between the House and Senate and a growing disagreement with the administration over President Trump’s plans for a border wall, both chambers were supportive of increasing funding for the National Institutes of Health (NIH). The House voted to support a $2 billion increase; the Senate Appropriations Committee supported a $3 billion increase.

When lawmakers returned to Washington on October 15, 2019, they had only five legislative weeks to work out unresolved disagreements in their appropriations bills before either reaching an agreement for full-year funding, passing another short-term measure, or facing a government shutdown. Complicating the progress on appropriations was the impeachment inquiry, which not only diverted attention, but also created greater fault lines between the two parties.

The Endocrine Society will continue to advocate for a final appropriations bill with at least a $2 billion increase for the NIH. We have testified before Congress, visited key leaders, and conducted Hill Days, but we need to keep the pressure on.

Please join us in advocating for endocrine-related research by joining our online advocacy campaign to urge your Representative and Senators to support NIH funding. Visit endocrine.org/takeaction.

You may also like

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

  • Endocrine Society Continues Global EDC Advocacy; EU Election Results Leaves Outcomes for EDC Legislation Uncertain  

    On June 17, the Endocrine Society joined delegations from dozens of countries gathered in Geneva, Switzerland, for the third session of an ad hoc open-ended working group (OEWG) convened under the United Nations Environment Programme (UNEP) to develop proposals to establish a new science policy panel charged with helping to inform governments, companies, farmers and…

Find more in